These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 34859955)
21. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753 [TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341 [TBL] [Abstract][Full Text] [Related]
23. C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema. Madsen DE; Sidelmann JJ; Biltoft D; Gram J; Hansen S Biochim Biophys Acta; 2015 Jun; 1850(6):1336-42. PubMed ID: 25800206 [TBL] [Abstract][Full Text] [Related]
24. HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure. Ow SY; Kapp EA; Tomasetig V; Zalewski A; Simmonds J; Panousis C; Wilson MJ; Nash AD; Pelzing M MAbs; 2023; 15(1):2163459. PubMed ID: 36628468 [TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial. Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447 [TBL] [Abstract][Full Text] [Related]
26. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Bork K; Kleist R; Hardt J; Witzke G Blood Coagul Fibrinolysis; 2009 Jul; 20(5):325-32. PubMed ID: 19474702 [TBL] [Abstract][Full Text] [Related]
27. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study. Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783 [TBL] [Abstract][Full Text] [Related]
28. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials. Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833 [TBL] [Abstract][Full Text] [Related]
29. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674 [TBL] [Abstract][Full Text] [Related]
30. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants. Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079 [TBL] [Abstract][Full Text] [Related]
31. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study. Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008 [TBL] [Abstract][Full Text] [Related]
32. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Kostic A; King TA; Yang F; Chan KC; Yancopoulos GD; Gromada J; Harp JB Diabetes Obes Metab; 2018 Feb; 20(2):283-291. PubMed ID: 28755409 [TBL] [Abstract][Full Text] [Related]
33. A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers. Mallory RM; Ali SO; Takas T; Kankam M; Dubovsky F; Tseng L Biologicals; 2017 Nov; 50():81-86. PubMed ID: 28844541 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075 [TBL] [Abstract][Full Text] [Related]
36. Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. Playford EG; Munro T; Mahler SM; Elliott S; Gerometta M; Hoger KL; Jones ML; Griffin P; Lynch KD; Carroll H; El Saadi D; Gilmour ME; Hughes B; Hughes K; Huang E; de Bakker C; Klein R; Scher MG; Smith IL; Wang LF; Lambert SB; Dimitrov DS; Gray PP; Broder CC Lancet Infect Dis; 2020 Apr; 20(4):445-454. PubMed ID: 32027842 [TBL] [Abstract][Full Text] [Related]
37. Factor XII(a) inhibitors: a review of the patent literature. Kalinin DV Expert Opin Ther Pat; 2021 Dec; 31(12):1155-1176. PubMed ID: 34142629 [No Abstract] [Full Text] [Related]
38. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. Hussaini A; Mukherjee R; Berdieva DM; Glogowski C; Mountfield R; Ho PTC Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766 [TBL] [Abstract][Full Text] [Related]
39. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Magyarics Z; Leslie F; Bartko J; Rouha H; Luperchio S; Schörgenhofer C; Schwameis M; Derhaschnig U; Lagler H; Stiebellehner L; Firbas C; Weber S; Campanaro E; Jilma B; Nagy E; Stevens C Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138568 [TBL] [Abstract][Full Text] [Related]
40. A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers. Staton TL; Peng K; Owen R; Choy DF; Cabanski CR; Fong A; Brunstein F; Alatsis KR; Chen H BMC Pulm Med; 2019 Jan; 19(1):5. PubMed ID: 30616547 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]